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Abstract 
 
Hotspot mutations in the promoter region of telomerase reverse transcriptase (TERT) have recently 
been described in several human tumor entities. These mutations result in an up-regulation of the 
telomerase complex activity and thus constitute a relevant mechanism for immortalization of tumors 
cells. Knowledge of the TERT promoter status in tumors is likely to be of interest for molecular 
classification and as a potential target for therapy. We, therefore, performed a systematic analysis of 
TERT promoter mutations in 1515 tumors of the human nervous system and its coverings including 
373 pediatric and 1142 adult patients. We detected a total of 327 mutations. TERT promoter mutations 
were exceedingly rare in tumors typically encountered in pediatric patients. In entities typically 
encountered in adult patients TERT promoter mutations were strongly associated with older age (p < 
0.0001). Highest mutation frequencies were detected in gliosarcomas (81 %), oligodendrogliomas (78 
%), oligoastrocytomas (58 %), primary glioblastomas (54 %) and solitary fibrous tumors (50 %). 
Related to other molecular alterations, TERT promoter mutations were strongly associated with 1p/19q 
loss (p < 0.0001), but inversely associated with loss of ATRX expression (p < 0.0001) and IDH1/IDH2 
mutations (p < 0.0001). 
Together, TERT promoter mutations are typically found in adult patients and occur in a highly tumor 
type-associated distribution.  
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Introduction 
 
Telomeres are composed of repetitive nucleotide sequences, which together with associated proteins 
constitute important structural elements at the end of chromosomes. Telomere length shortens with 
each cell division, and this degradation eventually leads to replicative senescence. Immortalization is a 
crucial bottleneck to be passed in the evolution of a cancer cell, and the ability to maintain telomere 
length is therefore a typical feature of neoplasia. Telomeres are extended by the protein complex 
telomerase, in which the enzyme telomerase reverse transcriptase (TERT) plays a pivotal role [33]. 
Previous studies have shown a strong expression of TERT in the vast majority of human cancers [29], 
although the underlying mechanisms of TERT up-regulation were largely unknown. Recently, several 
alterations within the TERT gene have been detected in human tumors. Single nucleotide 
polymorphisms in the TERT gene have been associated with telomere length and have been 
associated with risk for breast and ovarian cancer [3]. Also the methylation status of distinct CpG sites 
in the TERT promoter has been associated with TERT expression, tumor progression and poor 
prognosis in pediatric nervous system tumors [5]. The most frequent alteration in the TERT gene, 
somatic promoter mutations, have been described in melanoma [9,12,13], primary nervous system 
tumors [2,14,17,23,30], thyroid [15,16], hepatocellular carcinomas [21] and bladder [17] as well as 
many other tumor types [14,30]. Two essentially mutually exclusive hot spot mutations in the promoter 
region have been reported: a cytosine-to-thymine transition at chromosome 5 base position 1,295,228 
(C228T) or less frequently at base position 1,295,250 (C250T). Both changes create a new binding 
site for E-twenty-six (ETS) transcription factors, resulting in an up to 5-fold increased induction of the 
TERT gene [13]. 
Another mechanism known relevant for maintaining telomere length is alternate lengthening of 
telomeres (ALT) [4] which is a homologous recombination dependent process typically associated with 
mutations in the chromatin remodeling genes α-thalassemia/mental-retardation-syndrome-X-linked  
(ATRX) and death-associated protein 6 (DAXX) [11]. ALT has been demonstrated in gliomas and 
other tumors [7,8]. However, TERT promoter mutations appear to be the single most frequently 
occurring mechanism to affect telomere length. 
So far, the TERT promoter status has been published for 1507 nervous system tumors 
[2,14,17,23,30]. The vast majority of these tumors were from adult patients and 843/1507 tumors have 
been diagnosed as glioblastoma (supplementary table 1). In order to provide a comprehensive 
overview of the frequency of TERT promoter mutations we analyzed 1515 nervous system tumors 
covering a wide range of diagnoses from 373 pediatric and 1142 adult patients [19].  
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Material and Methods 
Tissue samples 
Tumor tissues for DNA extraction were obtained from the archives of the Institutes and Departments of 
Neuropathology at the University Hospitals Münster, Hannover, Frankfurt, Tübingen, Magdeburg and 
Heidelberg (Germany). Research use of tissues and anonymisation of data was in accordance with 
local ethical approvals. Tumors from patients younger than 18 years of age were termed pediatric and 
tumors from patients aged 18 or older were termed adult. Diagnosis, age and TERT promoter mutation 
status for each patient are given in supplementary table 2. Further molecular data is summarized for 
astrocytic tumors, oligododendroglial tumors and medulloblastomas in supplementary tables 3-5. 
 
DNA-based methods 
Amplicons of 163 bp spanning the hot-spot mutations at positions 1,295,228 and 1,295,250 on 
chromosome 5 were amplified using 20 ng each of the forward primer 5`CAGCGCTGCCTGAAACTC 
and the reverse primer 5`GTCCTGCCCCTTCACCTT. Primer design was based on accession number 
NC_000005.9. 80 ng of DNA and AccuPrime™ GC-Rich DNA Polymerase kit (Life Technologies, 
Darmstadt, Germany) were employed. PCR was performed in a total volume of 25 µl, and included 
initial denaturation at 95°C for 180 s, followed by 35 cycles with denaturation at 95°C for 30 s, 
annealing at 62°C for 25 s and extension at 72°C for 30 s. The amplification product was purified and 
cleaned up by agarose gel electrophoresis. Subsequently the 163 bp products were gel-extracted with 
the NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, Düren, Germany) according to the 
manufacturers’ protocol. Two µl of the purified amplification product was submitted to bidirectional 
sequencing using the BigDye Terminator v3.1 Sequencing Kit (Applied Biosystems, Foster City, CA, 
USA). Sequences were determined using an ABI 3500 Genetic Analyzer (Applied Biosystems) and the 
Sequence Pilot version 4.0.1 (JSI-Medisys, Kippenheim, Germany) software. 
Determination of hotspot mutations in BRAF and IDH1/2, and testing for 1p/19q LOH was carried out 
as previously described [10,25,26]. 
 
ATRX immunohistochemistry 
ATRX staining was performed as previously described [32]. In brief, ATRX polyclonal rabbit antibody 
(dilution 1:400, product code HPA001906, Sigma-Aldrich, St. Louis, MO, USA) was used. Staining was 
performed using an automated immunostainer (Benchmark Ultra, Ventana, Tucson, AZ, USA) and 
standard protocols including pretreatment using Cell Conditioning 1 buffer (Ventana) for 52 min and 
standard Ventana signal amplification. ATRX data have been reported in part previously [32]. 
 
Statistics 
Fisher’s exact test was used to examine associations between nominal variables. Student’s t test was 
used to examine the association between nominal variables and age.  
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Results and Discussion 
 
This study presents a comprehensive overview of TERT promoter mutations in tumors of the nervous 
system and its coverings. A total of 1515 tumors were tested and 327 TERT promoter mutations were 
found. The C228T mutation was detected 257 times making it more frequent than the C250T mutation 
seen in 68 cases. Two further mutation variants were sporadically observed: a pediatric glioblastoma 
with C228A mutation and a pleomorphic xanthoastrocytoma with C249T mutation. A summary of the 
pediatric and adult tumors and corresponding mutation rates for the TERT promoter are given in table 
1. Although TERT promoter mutations over-all were very frequent, we also detected significant 
differences between distinct tumor entities: 
 
Astrocytic tumors 
TERT promoter mutations were not detected in 111 pilocytic astrocytomas WHO grade I. Likewise, the 
rare variants of subependymal giant cell astrocytoma WHO grade I and pilomyxoid astrocytoma WHO 
grade II did not show this alteration. Pleomorphic xanthoastrocytomas WHO grade II (PXA II) had a 
low frequency of mutations with a single case out of 25 tested tumors bearing a unique C249T 
mutation. Pleomorphic xanthoastrocytomas with anaplastic features (PXA waf) exhibited TERT 
promoter mutations in 3/13 instances. All three patients were of older age. TERT promoter hotspot 
mutations create a new binding site for ETS transcription factors, which are partly regulated by the 
mitogen-activated protein kinase (MAP kinase) signaling pathway, in which BRAF acts as an upstream 
signaling kinase [31]. Furthermore, BRAF V600E is a hallmark mutation in PXAs [26] and leads to 
aberrant MAPK signaling [6]. Coincidental occurrence of BRAF V600E and TERT promoter mutations 
has been described in thyroid cancers [15,16]. However, in PXAs there was no association between 
TERT promoter and BRAF V600E mutation (p = 0.6; suppl. fig. 1a). 
Diffuse astrocytomas WHO grade II exhibited TERT promoter mutations in 8/25 cases and showed a 
strong inverse association with the presence of IDH1/IDH2 mutations (p < 0.05; suppl. fig. 1b) [14]. 
Similar observations were made for anaplastic astrocytoma WHO grade III with TERT promoter 
mutations in 30/118 cases, also inversely associated with IDH1/IDH2 (p < 0.0001; suppl. fig. 1c). 
ATRX alterations have been shown to closely overlap with IDH1/IDH2 and TP53 mutations in 
astrocytoma [18,32]. Likewise, we observed an inverse association between loss of ATRX expression 
and TERT promoter mutations (p < 0.05; suppl. fig. 1d). Primary glioblastoma in adults exhibited a 
high incidence of TERT promoter mutations (79/147, 54 %) while only 1/20 secondary glioblastomas 
had a mutation. For primary glioblastoma this matches previous observations and supports the inverse 
association of TERT promoter and IDH mutations. Our mutation frequency of 5 % in secondary 
glioblastomas is lower than the 28 % previously observed [23] although, the number of secondary 
glioblastomas in our series is rather small. The observation of TERT mutations in 33 % of diffuse 
astrocytomas and 28 % of anaplastic astrocytomas would also suggest a higher frequency of this 
alteration in secondary glioblastomas than identified in our series. The rare and controversially 
discussed glioblastoma with oligodendroglial differentiation exhibited TERT promoter mutation in 4/6 
cases. Because TERT promoter mutations are frequent in both, primary glioblastoma and anaplastic 
oligodendroglioma, this parameter most likely will not be helpful to contribute to the debate on the 
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origins of glioblastoma with oligodendroglial differentiation. Giant cell glioblastomas were mutated in 
6/17 cases. This variant has been shown to be strongly associated with TP53 mutations [20,24]. 
Gliosarcomas carried TERT promoter mutations in 21/26 instances, the highest mutation prevalence in 
our series. Among gliomatoses 7/10 tumors harbored the mutation. 
In opposition to adult patients, TERT promoter hotspot mutations were not present in pediatric primary 
glioblastomas except one case with a unique C228A mutation. Constitutional DNA from this patient 
was not available. However, single somatic C228A mutations have already been described in one 
ovarian carinoma and in two urothelial carcinomas [14]. In contrast to the C228T and C250T changes, 
the C228A alteration does not create the new binding site for ETS transcription factors. However, an 
effect of this alteration on binding of other transcription factors cannot be excluded. Our pediatric GBM 
with C228A mutation was wild type for H3F3A frequently been mutated in pediatric glioblastomas and 
typically associated with ATRX mutation and ALT characteristics [27]. ATRX mutations frequently 
occur in pediatric GBMs [27] and, in adult glioma, are mutually exclusive with TERT promoter mutation 
[2]. We detected ATRX mutation/loss of expression in 3/11 pediatric glioblastomas (fig. 1). Current 
data regarding the association of ALT status and ATRX loss in adult GBMs is controversial. While one 
series detected the presence of ALT in approximately 25 % [1] two other series detected ALT in less 
than 14 % [22] and 7 % [18] of adult GBM. Also, one series did not find a difference in frequency of 
ALT between adult and pediatric GBM [1] while another series found this alteration 3 times more 
frequent in pediatric glioblastoma [22]. While two studies found a tight correlation between ALT 
phenotype and loss of ATRX expression [1,22], another did not [18]. More comprehensive and 
histopathologically clearly defined series of tumors need to be examined in order to resolve these 
discrepancies. 
 
Oligodendroglial tumors 
TERT promoter mutations were found in 29/37 oligodendrogliomas WHO grade II and in 29/38 
anaplastic oligodendrogliomas WHO grade III. Oligoastrocytomas WHO grade II presented with TERT 
promoter mutations in 11/19 instances, while the incidence in anaplastic oligoastrocytomas WHO 
grade III was 45/86. Therefore, oligoastrocytomas had a lower prevalence of TERT promoter 
mutations than pure oligodendrogliomas. However, there was no increase of mutation frequency with 
increasing malignancy grade in oligodendroglial tumors. TERT mutations were frequent in 
oligodendroglial tumor entities, regardless of the WHO grade. Previous studies have highlighted the 
strong association of 1p/19q loss and TERT promoter mutations [2,14]. This is consistent with our 
series, in which oligodendroglial tumors with a combined 1p/19q loss were significantly more 
frequently TERT promoter mutated (49/56; 88 %) compared with oligodendroglial tumors with 1p/19q 
retention (8/22; 36 %) (p < 0.0001; suppl. fig. 1e). Loss of ATRX expression was observed in 13/55 
oligodendroglial tumors and inversely associated with TERT promoter mutations. Vice versa 28/42 
cases with retained ATRX expression were TERT promoter mutated (p < 0.0001; suppl. fig. 1f). 10/14 
ATRX expressing cases with TERT promoter wild type status were oligoastrocytomas. 
 
Ependymal tumors 
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TERT promoter mutations were found in 0/12 subependymomas WHO grade I and 0/14 myxopapillary 
ependymomas WHO grade I. 5/73 ependymomas WHO grade II and 2/46 anaplastic ependymomas 
WHO grade III had the TERT promoter mutation. All TERT mutations in ependymomas occurred in 
adult patients with these seven patients being aged between 55 and 67 years. Thus, TERT promoter 
mutations were absent in all pediatric ependymoma and in two subgroups of ependymoma graded 
WHO I i.e. the subependymomas and the myxopapillary ependymomas. Adult patients with WHO 
grade II and WHO grade III anaplastic ependymoma younger than 50 years did not carry TERT 
mutations while more than 25 % of the ependymoma patients 50 years or older had a TERT promoter 
mutation. 
 
Embryonal tumors 
In concordance with previous data [14] we detected TERT promoter mutations in 17/91 
medulloblastomas. 15 of the 17 patients with TERT mutations in medulloblastoma were of adult age 
and 15 of the mutated tumors were allotted to the SHH group of medulloblastoma. Thus, while rare in 
pediatric medulloblastomas (3 %), TERT mutations were very frequent in adult medulloblastomas (65 
%) and particular in adult SHH subgroup tumors (13/13, 100 %). In this patient set, we observed a 
strong prevalence of the C228T mutation. TERT promoter mutations were absent or seen only at very 
low frequency in all other embryonal tumor entities. 
 
Meningeal tumors 
Previous investigations have found no TERT promoter mutations in meningiomas [14]. Accordingly we 
detected no TERT promoter mutations in 91 meningiomas WHO grade I of different subtypes. 
However, in atypical (WHO grade II) and anaplastic/rhabdoid meningiomas (WHO grade III) we 
detected mutations in 2/49 and 6/37 instances, respectively. Thus, the frequency of TERT promoter 
mutations increased with higher malignancy. Hemangiopericytomas (HPC) and solitary fibrous tumors 
(SFT) have recently been shown to share the recurrent NAB2-STAT6 fusion that leads to a strong 
nuclear translocation of STAT6 [28]. This molecular hallmark alteration now allows for a sharp 
separation of HPCs/SFTs from atypical and anaplastic meningiomas. Since SFT/HPC both shared this 
gene fusion, we expected no pronounced difference in TERT promoter mutation frequency between 
the two entities. In a previously analyzed smaller series of SFT/HPC 2 of 10 cases showed TERT 
promoter mutations [14]. Interestingly, we detected mutations in only 3/27 HPCs but in 8/16 SFTs. 
This difference in TERT promoter mutation frequency between HPC and SFT is unexplained. No 
TERT promoter mutation was observed in 13 hemangioblastomas WHO grade I.  
 
Other tumors of the nervous system 
The other tumor groups as defined by WHO, including choroid plexus tumors, neuronal and mixed 
neuronal-glial tumors, tumors of the pineal region, tumors of the cranial and paraspinal nerves, tumors 
of the hematopoietic system with primary lymphomas and histiocytic tumors, germ cell tumors and 
tumor of the sellar region exhibited TERT promoter mutations in only a few single instances (table 1). 
For several of the rare entities, however, only low numbers of tumors were available for analysis. 
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TERT mutations in adult and pediatric patients with nervous system tumors 
A clear accumulation of TERT promoter mutations was seen in adult astrocytomas, glioblastomas and 
oligodendroglial tumors. Also the less frequent TERT promoter mutations in ependymoma exclusively 
occurred in adult patients of older age. A further group of special interest is adult patients with 
medulloblastoma, who in contrast to their pediatric counterparts exhibited a high incidence of TERT 
mutations. In addition, there also seems to be some association of TERT mutations with higher grades 
of malignancy in meningioma. 
In contrast to adults, pediatric patients very rarely exhibited TERT promoter mutations. Overall only 7 
TERT promoter mutations were observed in 373 pediatric tumors. This is of special interest in the case 
of tumors which occur across ages, e.g. medulloblastoma, glioblastoma and ependymoma, where 
TERT mutations were quite frequently observed in adult patients but not in children. The most frequent 
pediatric nervous system tumor, pilocytic astrocytoma WHO grade I also did not exhibit TERT 
promoter mutations. 
We analyzed the association of TERT promoter status with age for those entities with high TERT 
promoter mutation frequencies and with high numbers of patients included. We pooled astrocytomas 
WHO grade II and III, oligoastrocytomas WHO grade II and III, and oliogdendrogliomas WHO grade II 
and III because TERT promoter mutation frequencies were independent of grade within these entities. 
TERT promoter mutations were strongly confined to older age in glioblastomas (p < 0.001), 
astrocytomas (p < 0.001), oligoastrocytomas (p < 0.05), oligodendrogliomas (p < 0.05) and 
medulloblastomas (p < 0.001) (fig. 2 a-f). 
Our findings support that immortalization of tumor cells in pediatric nervous system tumor patients 
generally is not achieved by TERT promoter mutation mediated activation of telomerase. However, 
other mechanisms of telomerase activation might very well be of importance in this age group as 
demonstrated by a recent publication associating the methylation status of TERT with prognosis in 
pediatric nervous system tumors [5], and by the finding of ALT in a high proportion of pediatric 
glioblastomas [27]. 
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Conclusion 
TERT promoter mutations predominantly occur in glial tumors of adult patients. They are most 
frequent in astrocytic and oligodendroglial tumors of WHO grade II and higher. In contrast, pediatric 
nervous system tumor patients rarely have TERT promoter mutations. In those instances where TERT 
mutations were found in typical pediatric tumors, the patients were of older age.  
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Figure 1 
 
 
 
ATRX immunohistochemistry in a pediatric glioblastoma WHO grade IV (ID 63556) with nuclear 
expression of ATRX (a) and a pediatric glioblastoma WHO grade IV (ID 63566) with loss of nuclear 
ATRX expression but ATRX presence in reactive cells and endothelial cells (b). Vessels (arrow) serve 
as internal positive control. Magnification: 400-fold 
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Figure 2 
 
 
 
TERT promoter mutation status (wt/mut) in relation to age (years). TERT promoter mutation was 
significantly associated with younger patient age based on (a) all tumors (p < 0.0001), (b) 
glioblastomas (p < 0.0001), (c) astrocytomas WHO grade II and III (p < 0.0001), (d) oligoastrocytomas 
WHO grade II and III (p < 0.05), (e) oligodendrogliomas WHO grade II and III (p < 0.05), and (f) 
medulloblastomas (p < 0.0001).
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Table 1 
 
C228T and C250T TERT promoter mutations in tumors of the nervous system 
 
 
 
Tumor group 
 
 
Diagnosis (WHO grade) 
 
all 
N ; mut/wt % (C228/C250) 
 
 
pediatric (<18 years) 
N ; mut/wt % (C228/C250)
 
 
adult (>=18 years) 
N ; mut/wt % (C228/C250) 
 
     
Astrocytic tumors Pilocytic Astrocytoma (I) 111; 0/111 90 21 
Pilomyxoid Astrocytoma (II) 3;0/3 1 2 
Subependymal Giant Cell Astrocytoma (I) 10;0/10 5 5 
Pleomorphic Xanthoastrocytoma (II) 25; 1*/24 4%  10; 0/10 15; 1*/14 
Pleomorphic Xanthoastrocytoma with anaplastic features 13; 3/10 23% (2/1) 2 11; 3/8 (2/1) 
Diffuse Astrocytoma (II) 25; 8/17 32% (4/4) 1; 0/1 24; 8/16 33% (4/4) 
Anaplastic Astrocytoma (III) 118; 30/88 25% (24/6) 1; 0/1 117; 30/87 26% (24/6) 
Glioblastoma primary (IV) 147; 78/68+1** 54% (66/12) 32; 1**/31 3% 115; 78/37 68% (66/12) 
Glioblastoma secondary (IV) 20; 1/19 5% (0/1) - 20; 1/19 5% (0/1) 
Giant Cell Glioblastoma (IV) 17; 6/11 35% (4/2) - 17; 6/11 35% (4/2) 
Glioblastoma with oligodendroglial differentiation (IV) 6; 4/2 (3/1) - 6; 4/2 (3/1) 
Gliosarcoma (IV) 26; 21/5 81% (17/4) - 26; 21/5 81% (17/4) 
Gliomatosis 10; 7/3 70% (7/0) 1; 1/0 (1/0) 9; 6/3 66% (6/0) 
     
Oligodendroglial 
tumors 
Oligodendroglioma (II) 37; 29/8 78% (21/8) 2; 1/1 (0/1) 35; 28/7 80% (21/7) 
Anaplastic Oligodendroglioma (III) 38; 29/9 76% (20/9) - 38; 29/9 76% (20/9) 
Oligoastrocytoma (II) 19; 11/8 58% (9/2) 1; 0/1 18; 11/7 61% (9/2) 
Anaplastic Oligoastrocytoma (III) 86; 45/41 52% (37/8) - 86; 45/41 52% (37/8) 
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Ependymal 
tumors 
Subependymoma (I) 12; 0/12 - 12 
Myxopapillary Ependymoma (I) 14; 0/14 1 13 
Ependymoma (II) 73; 5/68 7% (5/0) 25; 0/25 48; 5/43 10% (5/0) 
Anaplastic Ependymoma (III) 48; 2/46 4% (1/1) 28; 0/28 20; 2/18 10% (1/1) 
     
Choroid plexus 
tumors 
Plexus Papilloma 13; 0/13 3 10 
Plexus Carcinoma 6; 1/5 (1/0) 3; 0/3 3; 1/2 (1/0) 
     
Other 
neuroepithelial 
tumors
Angiocentric Glioma (I) 9; 0/9 5 4 
    
     
Neuronal and 
mixed  
neuronal-glial 
tumors 
Desmoplastic Infantile Astrocytoma (I) 2; 0/2 2 - 
Desmoplastic Infantile Ganglioglioma (I) 6; 1/5 (1/0) 6; 1/5 (1/0) - 
Dysembryoplastic Neuroepithelial Tumor (I) 12; 0/12 5 7 
Ganglioglioma (I) 40; 1/39 2% (1/0) 17; 0/17 23; 1/22 (1/0) 
Anaplastic Ganglioglioma (III) 3; 0/3 - 3 
Gangliocytoma (I) 2; 0/2 1 1 
Neurocytoma (II) 28; 1/27 4% (1/0) 2; 0/2 26; 1/25 4% (1/0) 
Papillary Glioneuronal Tumor (I) 1; 0/1 1 - 
Rosette-forming Glioneuronal Tumor of the fourth Ventricle (I) 6; 0/6 1 5 
Paraganglioma (I) 12; 1/11 8% (1/0) - 12; 1/11 8% (1/0) 
     
Tumors of the 
pineal region 
Pineocytoma (I) 2; 0/2  2 
Pineal Parenchymal Tumor of Intermediate Differentiation (II) 9; 0/9 - 9 
Pineoblastoma (IV) 5; 0/5 1 4 
Papillary Tumor of the Pineal Region (II) 2; 0/2 - 2 
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Embryonal 
tumors 
Medulloblastoma (IV) 91; 17/75 18% (16/1) 68; 2/66 3% (1/1) 23; 15/8 65% (15/0) 
Ependymoblastoma/ETANTR/ETMR (IV) 13; 0/13 13 - 
Atypical Teratoid / Rhabdoid Tumor (IV) 19; 1/18 6% (1/0) 19; 1/18 6% (1/0) - 
Esthesioneuroblastoma 12; 0/12 - 12 
     
Tumors of the 
cranial  
and paraspinal 
nerves 
Schwannoma (I) 18; 0/18 - 18 
Neurofibroma (I) 17; 0/17 1 16 
Malignant Peripheral Nerve Sheath Tumor (IV) 12; 2/10 17% (1/1) - 12; 2/10 17% (1/1) 
     
Meningeal 
tumors 
Meningioma meningothelial (I) 19; 0/19 - 19 
Meningioma transitional (I) 25; 0/25 - 25 
Meningioma fibroblastic (I) 11; 0/11 - 11 
Meningioma psammomatous (I) 11; 0/11 - 11 
Meningioma secretory (I) 17; 0/17 - 17 
Meningioma angiomatous (I) 8; 0/8 - 8 
Meningioma atypical (II) 42; 2/40 5% (2/0) - 42; 2/40 5% (2/0) 
Meningioma chordoid (II) 5; 0/5 - 5 
Meningioma clear cell (II) 2; 0/2 1 1 
Meningioma anaplastic (III) 32; 4/28 13% (3/1) - 32; 4/28 13% (3/1) 
Meningioma rhabdoid (III) 5; 2/3 (1/1) 1 4; 2/2 (1/1) 
Hemangiopericytoma  27; 3/24 11% (2/1) - 27; 3/24 11% (2/1) 
Solitary Fibrous Tumor 16; 8/8 50% (6/2) - 16; 8/8 50% (6/2) 
Hemangioblastoma (I) 13; 0/13 1 12 
     
Tumors of the  
hematopoietic 
system
Lymphomas 12; 0/12 2 10 
Histiocytic Tumors 18; 0/18 6 12 
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Germ cell tumors Germinoma 7; 0/7 5 2 
Teratoma 4; 0/4 3 1 
Yolk Sac Tumor 4; 0/4 1 3 
Choriocarcinoma 4; 1/3 (0/1) - 4; 1/3 
     
Tumors of the 
sellar region 
Craniopharyngioma 18; 0/18 4 14 
Granular Cell Tumor 5; 1/4 (0/1) 1; 0/1 4; 1/3 (0/1) 
Pituicytoma 1; 0/1 - 1 
Pituitary Adenoma 11; 0/11 - 11 
 
 
* - pleomorphic xanthoastrocytoma with a C249T mutation; ** - pediatric glioblastoma with a C228A mutation
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